- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Locally Advanced HER2-negative Breast Cancer
Total 2530 results
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; iOMEDICO AGCompletedHer2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast CancerGermany
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma | Locally Advanced HER2-Negative...United States
-
Instituto do Cancer do Estado de São PauloFundação Faculdade de MedicinaTerminatedLocally Advanced HER2-negative Breast CancerBrazil
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Fudan UniversityRecruitingBreast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)China
-
Yongsheng WangJiangsu HengRui Medicine Co., Ltd.RecruitingLocally Advanced Breast Cancer | Hormone Receptor Positive,HER2-negative Breast CancerChina
-
EnhancedBio USA Inc.ZenopharmRecruitingMetastatic Breast Cancer | Locally Advanced Breast Cancer | HER2-Negative | Estrogen Receptor-PositiveUnited States, Korea, Republic of
-
University of WashingtonBreast Cancer Research FoundationNot yet recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma | Locally Advanced Unresectable HER2-Negative Breast Carcinoma | Locally Advanced Unresectable Hormone Receptor-Positive...United States
-
Alison StopeckRecruitingBreast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | TNBC, Triple Negative Breast Cancer | Locally Advanced Breast Cancer | Neoadjuvant ChemotherapyUnited States
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, Peru and more
-
Biocon Biologics UK LtdNot yet recruitingHR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Royal Marsden NHS Foundation TrustPfizer; Breast Cancer NowRecruitingMetastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Recurrent Breast Cancer | ER+ Breast CancerUnited Kingdom
-
University Hospital, AkershusVestre Viken Hospital Trust; NovartisRecruitingBreast Cancer | Locally Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Luminal A Breast Cancer | Luminal B Breast CancerNorway
-
QuantumLeap Healthcare CollaborativeRecruitingBreast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
Antonio Giordano, MDCardiff OncologyRecruitingBreast Cancer | Metastatic Breast Cancer | Inflammatory Breast Cancer | Invasive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Hormone Receptor Negative Breast Carcinoma | Hormone Receptor/Growth Factor...United States
-
Melinda TelliPfizer; BioMarin PharmaceuticalCompletedAdvanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast CancerUnited States
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
Instituto do Cancer do Estado de São PauloFundação Faculdade de MedicinaTerminatedLocally Advanced HER2-positive Breast CancerBrazil
-
Amunix, a Sanofi CompanyMerck Sharp & Dohme LLCRecruitingLocally Advanced or Metastatic HER2-Expressing CancersAustralia, Spain, France, Portugal
-
Hoffmann-La RocheCompletedHER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast CancerIndia
-
Tianjin Medical University Cancer Institute and...Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingHER2+ Early or Locally Advanced Breast Cancer
-
PfizerCompletedHR+/HER2- Locally Advanced, Metastatic Breast CancerUnited Kingdom
-
Hoffmann-La RocheWithdrawnBreast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Not yet recruitingMetastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast CancervUnited States
-
Japan Breast Cancer Research GroupChugai PharmaceuticalUnknownHER2-positive Locally Advanced or Metastatic Breast CancerJapan
-
Samsung Bioepis Co., Ltd.CompletedHER2 Positive Early or Locally Advanced Breast CancerCzechia
-
OncoTherapy Science, Inc.RecruitingRelapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast CancerUnited States
-
Guangdong Provincial People's HospitalSun Yat-sen University; First Affiliated Hospital, Sun Yat-Sen University; Shantou...RecruitingAdvanced Breast Cancer | HER2-negative Breast CancerChina
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Hoffmann-La RocheTerminatedEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerCanada, United States, United Kingdom, Australia, Germany
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
Stemline Therapeutics, Inc.CompletedAdvanced ER+, HER2-Negative Breast CancerUnited States
-
Cancer Trials IrelandTerminatedMetastatic Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast CancerIreland, Spain
-
HutchmedActive, not recruitingRectal Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Triple Negative Breast Cancer | Metastatic Colon Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast CancerUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHR-positive, HER2-negative Advanced Breast CancerChina
-
AstraZenecaActive, not recruitingAdvanced ER-Positive HER2-Negative Breast CancerUnited States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
-
wang shusenRecruitingAdvanced HER2 Negative Breast Carcinoma HRD+Breast CancerChina
-
Tianjin Medical University Cancer Institute and...RecruitingHR Positive HER2 Negative Advanced Breast CancerChina
-
Henan Cancer HospitalRecruitingHR Positive HER2 Negative Advanced Breast CancerChina
-
National University Hospital, SingaporeAdagene IncRecruitingAdvanced Solid Tumor | HER2-negative Breast CancerSingapore
-
Sun Pharma Advanced Research Company LimitedTerminatedAdvanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerUnited States, India
-
Tianjin Medical University Cancer Institute and...RecruitingAdvanced HER2 Negative Breast Carcinoma | HRD+Breast CancerChina
-
Henan Cancer HospitalNot yet recruitingAdvanced Breast Cancer | Treatment | HR Low/HER2 Negative
-
Hoffmann-La RocheRecruitingEstrogen Receptor-Positive, HER2-Negative Advanced Breast CancerBelgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Portugal, Spain, Taiwan, Costa Rica, New Zealand, Poland, Chile, Colombia, Guatemala, Israel